Can peptide receptor radionuclide therapy be safely applied in florid bone metastases of gastroenteropancreatic neuroendocrine tumours?

被引：0

作者：

Sabet, Amir ^{[1
]}

Yong-Hing, Charlotte ^{[2
]}

Ezziddin, Khaled ^{[1
]}

Ahmadzadehfar, Hojjat ^{[1
]}

Guhlke, Stefan ^{[1
]}

Gruenwald, Frank ^{[3
]}

Biersack, Hans Juergen ^{[1
]}

Ezziddin, Samer ^{[1
]}

机构：

[1] Dept Nucl Med, Bonn, Germany

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Univ Hosp, Frankfurt, Germany

来源：

JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

1183

引用

页数：2

共 50 条

[41] Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy [J].

Bodei, Lisa ;

Schoeder, Heiko ;

Baum, Richard P. ;

Herrmann, Ken ;

Strosberg, Jonathan ;

Caplin, Martyn ;

Oeberg, Kjell ;

Modlin, Irvin M. .

LANCET ONCOLOGY, 2020, 21 (09) :E431-E443

[42] Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours [J].

W. A. van der Zwan ;

T. Brabander ;

B. L. R. Kam ;

J. J. M. Teunissen ;

R. A. Feelders ;

J. Hofland ;

E. P. Krenning ;

W. W. de Herder .

European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 :704-717

[43] Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours [J].

van der Zwan, W. A. ;

Brabander, T. ;

Kam, B. L. R. ;

Teunissen, J. J. M. ;

Feelders, R. A. ;

Hofland, J. ;

Krenning, E. P. ;

de Herder, W. W. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) :704-717

[44] PEPTIDE RECEPTOR RADIONUCLIDE THERAPY: CAN WE SAFELY USE THIS IN CHRONIC KIDNEY DISEASE? [J].

Manohar, Sandhya ;

Halfdanarson, Thorvardur R. ;

Hobday, Timothy J. ;

Johnson, Geoffrey B. ;

Kendi, Ayse Tuba ;

Leung, Nelson .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (05) :701-701

[45] Peptide receptor radionuclide therapy of neuroendocrine tumors [J].

Haug, A. R. ;

Bartenstein, P. .

ONKOLOGE, 2011, 17 (07) :602-+

[46] Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy [J].

Rabei, Rana ;

Fidelman, Nicholas .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) :1994-2004

[47] Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy [J].

Rana Rabei ;

Nicholas Fidelman .

Current Treatment Options in Oncology, 2023, 24 :1994-2004

[48] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors [J].

Bodei, Lisa ;

Kidd, Mark ;

Prasad, Vikas ;

Modlin, Irvin M. .

NEUROENDOCRINE TUMORS: A MULTIDISCIPLINARY APPROACH, 2015, 44 :198-215

[49] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors [J].

Basu, Sandip ;

Parghane, Rahul, V ;

Kamaldeep ;

Chakrabarty, Sudipta .

SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (05) :447-464

[50] Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice [J].

Bournaud, C. ;

Kelly, A. ;

Hindie, E. ;

Tenenbaum, F. ;

Faivre-Chauvet, A. ;

Courbon, F. ;

Taieb, D. ;

Dierickx, L. O. ;

Coriat, R. ;

Ansquer, C. .

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2017, 41 (01) :42-54

← 1 2 3 4 5 →